Skip to content
Poster

Hepatoprotective effects of a semaglutide, elafibranor and resmetirom in the non-obese CDAA-HFD rat model of advanced MASH with progressive fibrosis

Background & Aim

Semaglutide (GLP-1 receptor agonist), elafibranor (dual PPAR-α/δ agonist), and resmetirom (THR-β agonist) have demonstrated therapeutic benefits in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). Resmetirom has recently been FDA approved as the first drug treatment for MASH.

The present study aimed to compare metabolic, biochemical and histological outcomes of semaglutide, elafibranor and resmetirom monotherapy in the non-obese choline-deficient L-amino-acid defined high-fat diet (CDAA-HFD) rat model of advanced MASH with progressive fibrosis.

Subjects
MouseCDAA-HFD ratBody weightBlood biochemistryInflammatory bowel diseaseMetabolic dysfunction-associated steatohepatitisElafibranorGLP-1 receptorHistopathology scoreImage analysisImmunohistochemistry (IHC)GLP-1Liver biopsyLiver morphometryTHR-ß receptorResmetiromSemaglutide

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top